ReviewNature reviews. Drug discovery2009
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Review in Nature reviews. Drug discovery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2,144 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2,144 citing papers in PubMed, 1 synthesis or guideline pooled it, 5,229 citations in OpenAlex.
- Natural Compounds for the Treatment of Cutaneous Squamous Cell Carcinoma: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Randomized, Double-Blind, Phase I Pharmacokinetic Study of Subcutaneous Recombinant Human Superoxide Dismutase (rhSOD) in Healthy Volunteers.Clinical pharmacokinetics · 2026Trial
- Thioredoxin reductase-1 facilitates cellular plasticity and stemness mediated by TGF-β1 in non-small cell lung cancer.Cancer biology & therapy · 2026Article
- Overcoming the blood‒brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease.Drug delivery · 2026Review
- Internalization ofAnnals of medicine · 2026Review
- Boldine enhances hyperthermia-induced apoptosis in AGS gastric cancer cells in association with attenuation of the HSF1-HSP stress response.Molecular biology reports · 2026Article
- A bibliometric analysis of global research trends in tumor microenvironment based nanotherapy.Discover nano · 2026Review
- Deep Learning-Based Multimodal Prediction of Neoadjuvant Chemotherapy Response in Locally Advanced Rectal Cancer by Integrating MRI and Proteomics.Cancer research and treatment · 2026Article
- Tumor microenvironment-rearranging Nanoassemblies overcome angiogenesis-immunotherapy resistance to potentiate osteosarcoma treatment.Materials today. Bio · 2026Article
- Platinum(IV) Complexes Suppress Tumor Growth in MDA-MB-231 Cells and a DMBA- Induced Mammary Carcinoma Model.Pharmaceutical research · 2026Article
- Mitochondria-Directed Redox Phospholipid Polymers for Cancer Therapy.Cancer science · 2026Article
- Alkaloids Reported in the GenusInternational journal of molecular sciences · 2026Review
- Engineered indoleamine 2,3-dioxygenase variant: Oxidative activation of prodrug indole-3-acetic acid against cancer cells for targeted therapy.Molecular therapy. Oncology · 2026Article
- HIF1α-KLF4 signaling dictates extra-erythrocyte expression of hemoglobin conferring sorafenib resistance in hepatocellular carcinoma.Signal transduction and targeted therapy · 2026Article
- Nanoantioxidants: Structure-Activity Relationships, Redox Mechanisms, Applications, and Safety.Antioxidants (Basel, Switzerland) · 2026Review
- SUMOylated Reptin maintains low intracellular ROS levels by activating mitophagy to drive gemcitabine resistance in gallbladder cancer.Cell death & disease · 2026Article
- TPGS-stabilized pyrimethamine micelles promote ROS-associated apoptosis in MDA-MB-231 cells and suppress tumour progression in a murine lymphoma model.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS-Responsive Therapeutics.Cell biochemistry and function · 2026Review
- Ascorbate-driven quinone redox cycling as a pro-oxidant anticancer strategy.Redox biology · 2026Review
- Exploiting vitamin C as a prooxidant to activate ROS-responsive prodrugs for potent and selective tumor killing.Redox biology · 2026Article
2,084 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.